Bigtincan (ASX:BTH), the leader in mobile, AI-powered sales enablement automation, today announced it has been recognized as a Representative Vendor of Sales Engagement Platforms in all of the capabilities defined by Gartner as part of the August 2019 Market Guide for Sales Enablement Platforms* for the second consecutive year. According to the report, “sales engagement platforms expand sales enablement capabilities by using information about buyer and seller engagement to deliver be...
SOURCE
READ MORE
|
Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with Tokyo Institute of Technology for the project, which has financial backing from Mitsubishi UFJ Capital. The research programme will be conducted by a newly-formed company called OiDE BetaRevive, with Daiichi Sankyo taking an option to buy the firm outright if it passes the proof-of-concept stage. T...
READ MORE
|
She’s a multi award-winning pharmacist and shares a name (almost) with the federal health minister. And now Susan Lee has been crowned Tasmanian pharmacist of the year for 2016. Over almost two.....
PHARMACYNEWS.COM.
READ MORE
|
President Donald Trump supports Medicare drug price negotiations, his spokesman said Tuesday, remarks that sent pharmaceutical stocks swinging again as investors tried to assess whether drugmakers will be forced into bidding wars for government business. “He’s for it, yes,” White House spokesman Sean Spicer said at a press briefing in response to a question asking to clarify Trump’s position on the matter....
READ MORE
|
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids....
READ MORE
|
Small Boston-based Pieris Pharmaceuticals is joining forces with AstraZeneca to speed development of its protein platform for application in respiratory diseases, announcing Wednesday a broad collaboration with the British pharma....
READ MORE
|